A Longitudinal Hepatitis B Vaccine Cohort Demonstrates Long-lasting Hepatitis B Virus (HBV) Cellular Immunity Despite Loss of Antibody Against HBV Surface Antigen

Journal of Infectious Diseases

Volumn 214, Issue 2, 2016, Pages 273-280

  Simons, Brenna C ^a,b,c   Spradling, Philip R ^d   Bruden, Dana J T ^b   Zanis, Carolyn ^b   Case, Samantha ^b   Choromanski, Tammy L ^a   Apodaca, Minjun ^e   Brogdon, Hazel D ^c   Dwyer, Gaelen ^c   Snowball, Mary ^a   Negus, Susan ^a   Bruce, Michael G ^b   Morishima, Chihiro ^e   Knall, Cindy ^c   McMahon, Brian J ^a,b  

^a ALASKA NATIVE TRIBAL HEALTH CONSORTIUM   (United States)

^b NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^c UNIVERSITY OF ALASKA ANCHORAGE   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Antibody against hepatitis B surface antigen; Booster vaccination; Cellular immunity; Hepatitis B virus; Plasma derived vaccine; Vaccine

Indexed keywords

HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; INTERLEUKIN 10; INTERLEUKIN 6; MICRORNA 155; TUMOR NECROSIS FACTOR ALPHA; HEPATITIS B ANTIBODY; MICRORNA; MIRN155 MICRORNA, HUMAN;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; CELLULAR IMMUNITY; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; CYTOMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; HUMAN CELL; LONGITUDINAL STUDY; MALE; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; SEROLOGY; T LYMPHOCYTE; BLOOD; CYTOLOGY; ENZYME LINKED IMMUNOSPOT ASSAY; HEPATITIS B VIRUS; IMMUNOLOGY; MIDDLE AGED; TIME FACTOR;

ADULT; CYTOLOGICAL TECHNIQUES; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HUMANS; IMMUNITY, CELLULAR; LONGITUDINAL STUDIES; MALE; MICRORNAS; MIDDLE AGED; T-LYMPHOCYTES; TIME FACTORS;

EID: 84977178314     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiw142     Document Type: Article

References (50)

1. Dentinger CM, McMahon BJ, Butler JC, et al. Persistence of antibody to hepatitis B and protection from disease among Alaska natives immunized at birth. Pediatr Infect Dis J 2005; 24:786-92.
2. Harpaz R, McMahon BJ, Margolis HS, et al. Elimination of new chronic hepatitis B virus infections: results of the Alaska immunization program. J Infect Dis 2000; 181:413-8.
3. McMahon BJ, Bulkow LR, Singleton RJ, et al. Elimination of hepatocellular carcinoma and acute hepatitis B in children 25 years after a hepatitis B newborn and catch-up immunization program. Hepatology 2011; 54:801-7.
4. Beasley RP, Hwang LY, Lee GC, et al. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet 1983; 2:1099-102.
5. Hadler SC, Francis DP, Maynard JE, et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med 1986; 315:209-14.
6. Szmuness W, Stevens CE, Harley EJ, et al. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med 1980; 303:833-41.
7. Van Damme P, Banatvala JE. Vaccine induced protection against hepatitis B. BMJ 2003; 326:105.
8. Centers for Disease Control and Prevention. Assessing completeness of perinatal hepatitis B virus infection reporting through comparison of immunization program and surveillance data-United States. MMWR Morb Mortal Wkly Rep 2011; 60:410-3.
9. Heyward WL, Bender TR, McMahon BJ, et al. The control of hepatitis B virus infection with vaccine in Yupik Eskimos. Demonstration of safety, immunogenicity, and efficacy under field conditions. Am J Epidemiol 1985; 121:914-23.
10. Petersen KM, Bulkow LR, McMahon BJ, et al. Duration of hepatitis B immunity in low risk children receiving hepatitis B vaccinations from birth. Pediatr Infect Dis J 2004; 23:650-5.
11. Hammitt LL, Hennessy TW, Fiore AE, et al. Hepatitis B immunity in children vaccinated with recombinant hepatitis B vaccine beginning at birth: a follow-up study at 15 years. Vaccine 2007; 25:6958-64.
12. Samandari T, Fiore AE, Negus S, et al. Differences in response to a hepatitis B vaccine booster dose among Alaskan children and adolescents vaccinated during infancy. Pediatrics 2007; 120:e373-81.
13. Su FH, Chu FY, Bai CH, et al. Efficacy of hepatitis B vaccine boosters among neonatally vaccinated university freshmen in Taiwan. J Hepatol 2013; 58:684-9.
14. Lin AW, Wong KH. Long-term protection of neonatal hepatitis B vaccination in a 30-year cohort in Hong Kong. J Hepatol 2013; 59:1363-4.
15. Su FH, Bai CH, Chu FY, Lin YS, Su CT, Yeh CC. Significance and anamnestic response in isolated hepatitis B core antibody-positive individuals 18 years after neonatal hepatitis B virus vaccination in Taiwan. Vaccine 2012; 30:4034-9.
16. Su FH, Chen JD, Cheng SH, Sung KY, Jeng JJ, Chu FY. Waning-off effect of serum hepatitis B surface antibody amongst Taiwanese university students: 18 years postimplementation of Taiwan's national hepatitis B vaccination programme. J Viral Hepat 2008; 15:14-9.
17. Yuen MF, LimWL, Cheng CC, LamSK, Lai CL. Twelve-year follow-up of a prospective randomized trial of hepatitis B recombinant DNA yeast vaccine versus plasmaderived vaccine without booster doses in children. Hepatology 1999; 29:924-7.
18. Poovorawan Y, Chongsrisawat V, Theamboonlers A, Bock HL, Leyssen M, Jacquet JM. Persistence of antibodies and immune memory to hepatitis B vaccine 20 years after infant vaccination in Thailand. Vaccine 2010; 28:730-6.
19. Bruce MG, Bruden D, Hurlburt D, et al. Antibody levels and protection after hepatitis B vaccine: results of a 30-year follow-up study and response to a booster dose. J Infect Dis 2016; 214:16-22.
20. McMahon BJ, Dentinger CM, Bruden D, et al. Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose. J Infect Dis 2009; 200:1390-6.
21. Williams JL, Christensen CJ, McMahon BJ, et al. Evaluation of the response to a booster dose of hepatitis B vaccine in previously immunized healthcare workers. Vaccine 2001; 19:4081-5.
22. Wainwright RB, McMahon BJ, Bulkow LR, Parkinson AJ, Harpster AP. Protection provided by hepatitis B vaccine in a Yupik Eskimo population. Seven-year results. Arch Intern Med 1991; 151:1634-6.
23. Wainwright RB, McMahon BJ, Bulkow LR, et al. Duration of immunogenicity and efficacy of hepatitis B vaccine in a Yupik Eskimo population. JAMA 1989; 261:2362-6.
24. McMahon BJ, Helminiak C, Wainwright RB, Bulkow L, Trimble BA, Wainwright K. Frequency of adverse reactions to hepatitis B vaccine in 43, 618 persons. Am J Med 1992; 92:254-6.
25. Wainwright RB, Bulkow LR, Parkinson AJ, Zanis C, McMahon BJ. Protection provided by hepatitis B vaccine in a Yupik Eskimo population-results of a 10-year study. J Infect Dis 1997; 175:674-7.
26. McMahon BJ, Bruden DL, Petersen KM, et al. Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up. Ann Intern Med 2005; 142:333-41.
27. Keating SM, Heitman JD, Wu S, et al. Cytokine and chemokine responses in the acute phase of hepatitis B virus replication in naive and previously vaccinated blood and plasma donors. J Infect Dis 2014; 209:845-54.
28. Zhu CL, Liu P, Chen T, et al. Presence of immunememory and immunity to hepatitis B virus in adults after neonatal hepatitis B vaccination. Vaccine 2011; 29:7835-41.
29. Chinchai T, Chirathaworn C, Praianantathavorn K, et al. Long-term humoral and cellular immune response to hepatitis B vaccine in high-risk children 18-20 years after neonatal immunization. Viral Immunol 2009; 22:125-30.
30. Lu CY, Ni YH, Chiang BL, et al. Humoral and cellular immune responses to a hepatitis B vaccine booster 15-18 years after neonatal immunization. J Infect Dis 2008; 197:1419-26.
31. Werner JM, Abdalla A, Gara N, Ghany MG, Rehermann B. The hepatitis B vaccine protects re-exposed health care workers, but does not provide sterilizing immunity. Gastroenterology 2013; 145:1026-34.
32. Werner JM, Abdalla A, Gara N, Ghany MG, Rehermann B. Innate and adaptive immune responses correlate to antibody recall responses to hepatitis B booster vaccineation. Hepatology 2013; 58:612A-3.
33. Bauer T, Jilg W. Hepatitis B surface antigen-specific T and B cell memory in individuals who had lost protective antibodies after hepatitis B vaccination. Vaccine 2006; 24:572-7.
34. Huang LM, Chiang BL, Lee CY, Lee PI, Chi WK, Chang MH. Long-term response to hepatitis B vaccination and response to booster in children born to mothers with hepatitis B e antigen. Hepatology 1999; 29:954-9.
35. Livingston SE, Simonetti JP, McMahon BJ, et al. Hepatitis B virus genotypes in Alaska Native people with hepatocellular carcinoma: preponderance of genotype F. J Infect Dis 2007; 195:5-11.
36. Simons BC, Vancompernolle SE, Smith RM, et al. Despite biased TRBV gene usage against a dominant HLA B57-restricted epitope, TCR diversity can provide recognition of circulating epitope variants. J Immunol 2008; 181:5137-46.
37. Liang M, Ma S, Hu X, et al. Cellular immune responses in patients with hepatitis B surface antigen seroclearance induced by antiviral therapy. Virol J 2011; 8:69.
38. Baquir B, Lin L, Ibrahim AS, et al. Immunological reactivity of blood from healthy humans to the rAls3p-N vaccine protein. J Infect Dis 2010; 201:473-7.
39. Zhang S, Desrosiers J, Aponte-Pieras JR, et al. Human immune responses to H. pylori HLA Class II epitopes identified by immunoinformatic methods. PLoS One 2014; 9:e94974.
40. McAdams RM, Bierle CJ, Boldenow E, et al. Choriodecidual group B streptococcal infection induces miR-155-5p in the fetal lung in macaca nemestrina. Infect Immun 2015; 83:3909-17.
41. Galli G, Nuti S, Tavarini S, et al. Innate immune responses support adaptive immunity: NKT cells induce B cell activation. Vaccine 2003; 21(suppl 2):S48-54.
42. Bendelac A, Savage PB, Teyton L. The biology of NKT cells. Annu Rev Immunol 2007; 25:297-336.
43. Bulkow LR, Wainwright RB, McMahon BJ, Parkinson AJ. Increases in levels of antibody to hepatitis B surface antigen in an immunized population. Clin Infect Dis 1998; 26:933-7.
44. Petersen NJ, Barrett DH, Bond WW, et al. Hepatitis B surface antigen in saliva, impetiginous lesions, and the environment in two remote Alaskan villages. Appl Environ Microbiol 1976; 32:572-4.
45. Favero MS, BondWW, Petersen NJ, Berquist KR, Maynard JE. Detection methods for study of the stability of hepatitis B antigen on surfaces. J Infect Dis 1974; 129:210-2.
46. Petersen NJ, Bond WW, Marshall JH, Favero MS, Raij L. An air sampling technique for hepatitis B surface antigen. Health Lab Sci 1976; 13:233-7.
47. Chen K, Rajewsky N. The evolution of gene regulation by transcription factors and microRNAs. Nat Rev Genet 2007; 8:93-103.
48. Lindsay MA. MicroRNAs and the immune response. Trends Immunol 2008; 29:343-51.
49. Pritchard CC, Cheng HH, Tewari M. MicroRNA profiling: approaches and considerations. Nat Rev Genet 2012; 13:358-69.
50. Xiong Y, Chen S, Liu L, Zhao Y, LinW, Ni J. Increased serum microRNA-155 level associated with nonresponsiveness to hepatitis B vaccine. Clin Vaccine Immunol 2013; 20:1089-91.